We’re on a mission!
MY01 Inc. is on a mission to empower healthcare professionals with the ability to pre-empt severe medical conditions thereby improving patient outcomes.
We believe that adding actionable quantitative data at the bedside during these interactions is the best way to make a meaningful impact to the patient while improving the experience of providing care. MY01 Inc. focuses on delivering actionable data at the bedside to augment clinical assessments. Qualitative People to People Assessments are at the core of personalized healthcare.
Nationalities in Our Team
Physician-Patient engagement is key to effective healthcare.
Healthcare is human.
Edward Harvey, MDCM
Chief Medical Officer
Charles Allan, M.Eng
Chief Executive Officer
George Xereas, PhD
Chief Technology Officer
Dr Harvey has a rich history of collaboration with basic, clinical and engineering scientists. He is a tenured Professor of Surgery at McGill University. He is the Director of the Injury Repair and Rehabilitation program (one of only eight programs that make up the entire institute) at the MUHC-RI with over 100 investigators in his group. He is, or has been, editor-in-chief of the Canadian Journal of Surgery; editorial board member of the Journal of Orthopaedic Trauma and OTA International; chairman of the Research Committee and of the Annual Basic Science Course of the OTA; chair of the Trauma Section at the ORS; and president of the Canadian Orthopaedic Association amongst other national and international positions.
Charles has a passion for solving problems with MEMS technology. Prior to NXTSENS Microsystems Inc., he completed an M. Eng. at McGill University where he led an engineering team developing high precision MEMS absolute pressure sensors. In his B.Eng., Charles led a team that developed a miniature glaucoma pump. Currently he is leading the commercialization efforts of MY01, leveraging his passions for both business and engineering to ensure optimal user experience and adoption.
Dr. Xereas obtained his Ph.D. in Electrical Engineering from McGill University in 2017, under a fellowship from Les Vadasz Foundation – Intel. The results of this work lead to a MEMS oscillator that for the first time achieved compliance with the stringent phase-noise GSM specifications. The intellectual property developed in his PhD resulted in 14 publications, and 2 USPTO utility patent applications. He is a co-founder and Chief Technology Officer of MY01 Inc.
We started as a Master’s project at McGill University. Founders, Dr. Ed Harvey, Charles Allan and George Xereas, worked on developing a MEMS-based pressure sensor that acts as a reliable ACS diagnostic tool. As we continued development we realized that we could apply our knowledge to broader applications, tackling other healthcare challenges.
What started off as a Master’s project at McGill University becomes an official startup as our founders: Charles, Ed and George, officially register the project as a corporate entity.
Spring & Summer, 2016
Nxtsens Takes the Cup: Dobson Cup & X-1
Nxtsens, our parent company, was awarded second place in the health science track at the McGill flagship startup competition, the McGill Dobson Cup. We followed this achievement with our participation in the X-1 program, a Montreal-based accelerator, during the summer of 2016.
MY01 Cracks the Top 50 at MedTech
We are selected out of 600 applicants to pitch at the MedTech Innovator Showcase, a medical technology industry’s global showcase and accelerator. Our participation leads us to rank amongst the Top 50 in the showcase.
Moving Day: MY01 moves to 85 Rue St. Paul West
As the company continues to rapidly expand, we outgrown our previous co-working space. Our team moves into an exciting, new, dedicated office space in the old port of Montreal.
MY01 in the Top 20 of the MedTech Innovator Accelerator
We are selected as a part of the top 20 amongst 700 applicants worldwide of the MedTech Innovator, a global competition and accelerator for medical devices, digital health and diagnostic companies.
MY01 Wins at the Medtech Conference in Philadelphia
Simon and Charles travel to Philadelphia to introduce MY01 to potential partner companies and investors at the Medtech Conference in Philadelphia where we win an award for “Best Video”.
We were awarded a prize for exemplary integration of its immigrant workforce
At MY01, we are extremely proud of our diversity, most of our employees are first generation immigrants. With many expressing interest in joining the Ordre des Ingénieurs du Québec, we started offering French in the office with French proficiency being a requirement to join the OIQ. We were recognized as an exemplary employer for integration of its immigrant workforce by the Office Québecois de la Langue Française.
MY01 passes ISO 13485 :2016 Audit
MY01’s Quality Management System (QMS) has been deemed compliant with the International Standard ISO 13485 “Medical devices — Quality Management Systems”
MY01 Receives CE Mark
MY01 has received positive notice from the European Commission for our MY01 Compartmental Pressure Monitor Device. We can now begin selling our device across the European Union.
MY01 receives MDSAP
MY01 has received its Medical Device Single Audit Program Certificate. The document certifies the compliance of our Quality Management System and allows us to apply for regulatory approvals in the US and in Canada.
MY01 Receives Health Canada Medical Device Licence
MY01 has received positive notice from Health Canada for our MY01 Compartmental Pressure Monitor Device. We can now begin selling our device across Canada.
MY01 receives 510k Clearance
MY01 has received its 510k clearance from the Food & Drug Administration (FDA) for its MY01 Compartmental Pressure Monitor.
MY01 moves into its new office
As the company has been growing at an impressive rate we had outgrown our old offices and had to size up with brand new offices in the heart of downtown Montreal at 400 Boul de Maisonneuve West, Suite 700.
MY01 launches its online learning center
MY01 Inc. has launched its online learning platform focused on keeping various stakeholders up to speed on current literature related to compartment syndrome, our most recent peer reviewed publications, and documentation related to our value proposition. Click here to visit
The MY01 Mobile Application receives FDA 510k clearance
MY01 has received a 510k clearance for the companion MY01 Mobile Application.
MY01 granted Breakthrough Device Designation
MY01 Inc. has received its first-ever “Breakthrough Device” designation by the FDA in October, joining a select list of Orthopaedic companies to receive this designation since the program began in 2016.